Alterations of the genes involved in the PI3K and estrogen-receptor pathways influence outcome in human epidermal growth factor receptor 2-positive and hormone receptor-positive breast cancer patients treated with trastuzumab-containing neoadjuvant chemotherapy.

Abstract

BACKGROUND:

Chemotherapy with trastuzumab is widely used for patients with human epidermal growth factor receptor 2-positive (HER2+) breast cancer, but a significant number of patients with the tumor fail to respond, or relapse. The mechanisms of recurrence and biomarkers that indicate the response to the chemotherapy and outcome are not fully investigated.

METHODS:

Genomic alterations were analyzed using single-nucleotide polymorphism arrays in 46 HER2 immunohistochemistry (IHC) 3+ or 2+/fluorescent in situ hybridization (FISH)+ breast cancers that were treated with neoadjuvant chemotherapy with paclitaxel, cyclophosphamid, epirubicin, fluorouracil, and trastuzumab. Patients were classified into two groups based on presence or absence of alterations of 65 cancer-associated genes, and the two groups were further classified into four groups based on genomic HER2 copy numbers or hormone receptor status (HR+/-). Pathological complete response (pCR) and relapse-free survival (RFS) rates were compared between any two of the groups.

RESULTS AND DISCUSSION:

The pCR rate was 54% in 37 patients, and the RFS rate at 3 years was 72% (95% CI, 0.55-0.89) in 42 patients. The analysis disclosed 8 tumors with nonamplified HER2 and 38 tumors with HER2 amplification, indicating the presence of discordance in tumors diagnosed using current HER2 testing. The 8 patients showed more difficulty in achieving pCR (P=0.019), more frequent relapse (P=0.018), and more frequent alterations of genes in the PI3K pathway (P=0.009) than the patients with HER2 amplification. The alterations of the PI3K and estrogen receptor (ER) pathway genes generally indicated worse RFS rates. The prognostic significance of the alterations was shown in patients with a HR+ tumor, but not in patients with a HR- tumor when divided. Alterations of the PI3K and ER pathway genes found in patients with a HR+ tumor with poor outcome suggested that crosstalk between the two pathways may be involved in resistance to the current chemotherapy with trastuzumab.

CONCLUSIONS:

We recommend FISH analysis as a primary HER2 testing because patients with IHC 2+/3+ and nonamplified HER2 had poor outcome. We also support concurrent use of trastuzumab, lapatinib, and cytotoxic and anti-hormonal agents for patients having HR+ tumors with alterations of the PI3K and ER pathway genes.

• Authors: Mamoru Takada, Toru Higuchi, Katsunori Tozuka, Hiroyuki Takei, Masayuki Haruta, Junko Watanabe, Fumio Kasai, Kenichi Inoue, Masafumi Kurosumi, Masaru Miyazaki, Aiko Sato-Otsubo, Seishi Ogawa, Yasuhiko Kaneko
• Journal: BMC cancer (BMC Cancer) Vol. 13 Pg. 241 (May 16 2013) ISSN: 1471-2407 [Electronic] England
• PMID: 23679233 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)

Chemical References

• Antibodies, Monoclonal, Humanized
• Receptors, Estrogen
• Receptors, Progesterone
• Epirubicin
• Cyclophosphamide
• Phosphatidylinositol 3-Kinases
• ERBB2 protein, human
• Receptor, ErbB-2
• Trastuzumab
• Paclitaxel
• Fluorouracil

Topics

• Antibodies, Monoclonal, Humanized (administration & dosage)
• Antineoplastic Combined Chemotherapy Protocols (therapeutic use)
• Breast Neoplasms (genetics, metabolism, therapy)
• Chemotherapy, Adjuvant
• Chromosome Aberrations
• Cyclophosphamide (administration & dosage)
• Disease-Free Survival
• Epirubicin (administration & dosage)
• Female
• Fluorouracil (administration & dosage)
• Gene Dosage
• Humans
• Immunohistochemistry
• In Situ Hybridization, Fluorescence
• Kaplan-Meier Estimate
• Neoadjuvant Therapy
• Oligonucleotide Array Sequence Analysis
• Paclitaxel (administration & dosage)
• Phosphatidylinositol 3-Kinases (metabolism)
• Polymorphism, Single Nucleotide
• Receptor, ErbB-2 (genetics, metabolism)
• Receptors, Estrogen (metabolism)
• Receptors, Progesterone (metabolism)
• Signal Transduction (genetics)
• Survival Rate
• Trastuzumab